ADMA Biologics, Inc. (ADMA) 股票分析

公司概述

ADMA Biologics, Inc. operates as a biopharmaceutical entity dedicated to the development, manufacturing, and marketing of specialty plasma-derived biologics designed to treat immune deficiencies and infectious diseases within both the United States and international markets. The company functions within the Healthcare sector and specifically within the Biotechnology industry, positioning itself to leverage biological mechanisms for therapeutic solutions rather than traditional small-molecule drugs. In terms of scale, the firm holds a market capitalization of $2.37B and generates annual revenue of $510.17M, supported by a workforce of 640 employees. These financial metrics indicate that ADMA has established a substantial presence in the specialized plasma market, suggesting significant operational capacity and a valuation that reflects investor confidence in its proprietary biologics pipeline and manufacturing infrastructure.

财务健康

The company reported revenue of $510.17M over the trailing twelve months, with a corresponding net income of $146.93M and an EBITDA of $199.54M. The notable gap between revenue and net income, alongside the operating margin of -123.4%, reveals a complex cost structure where operating expenses significantly exceed gross profit in the short term, despite a robust gross margin of 57.4%. This operating loss suggests that the company is likely investing heavily in research, development, or expansion costs that have not yet been fully offset by operating synergies, even though the core product profitability remains high. The free cash flow stands at -$18,154,876, indicating a current cash outflow that implies the company is prioritizing capital expenditures or strategic growth initiatives over immediate cash preservation. While the operating cash flow is negative, the balance sheet shows a cash position of $55.92B against total debt of $97.67B, creating a unique liquidity scenario where cash reserves vastly exceed debt obligations. The debt-to-equity ratio is 110.67, which appears leveraged on paper but is mitigated by the substantial cash holdings, effectively reducing net leverage. Liquidity is further evidenced by a current ratio of 6.71, indicating a highly conservative short-term liquidity position where current assets are more than six times current liabilities. Return on Equity is 35.6% and Return on Assets is 21.5%, metrics that reveal exceptional management effectiveness in generating returns on the capital base and assets, respectively, despite the reported operating margin contraction.

估值评估

The trailing P/E ratio is 16.57, while the forward P/E is 7.20, a significant disparity that implies the market expects earnings growth to accelerate substantially in the coming year relative to historical performance. The price-to-book ratio stands at 4.95, indicating that the market values the company at nearly five times its book value, suggesting a premium assigned to its intangible assets, intellectual property, and growth potential. Alternative valuation metrics such as the price-to-sales ratio of 4.64 and the EV/EBITDA of 221.08 further highlight the high valuation multiples often found in biotechnology firms with strong growth prospects but potentially volatile earnings. The stock has traded between a 52-week low of $7.21 and a 52-week high of $25.67, and without the specific current price provided in the facts, the exact percentage position relative to this range cannot be calculated, though the range demonstrates significant intrayear volatility. The beta value of 0.82 suggests that the stock's price volatility is lower than the broader market, indicating it may be less sensitive to general market fluctuations than large-cap technology or healthcare peers.

Growth & Income

Revenue growth year-over-year is 15.9%, while earnings growth is marked as N/A, indicating that the current earnings expansion has not yet reached a measurable annualized pace comparable to the revenue trajectory. The absence of reported earnings growth data alongside strong revenue expansion suggests the company is in a transitional phase where revenue scaling precedes normalized earnings acceleration. As a non-dividend payer, the company maintains a dividend yield of N/A and a payout ratio of 0.0%, meaning that all earnings are reinvested into the business rather than distributed to shareholders. This reinvestment strategy is typical for biotechnology companies aiming to fund ongoing research, manufacturing scale-up, or market expansion to sustain long-term growth. The overall growth and income profile is characterized by double-digit revenue expansion and a complete retention of earnings to fuel future developments, with no reliance on dividend income for investors.